Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)

NCT ID: NCT03334864

Last Updated: 2023-09-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

5000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-03

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators propose to establish and maintain a cohort of patients with advanced non-small cell lung cancer, and to assess the treatment pattern, host genetic, and clinical factors which influence the prognosis and survival, as well as the interaction among these factors on disease diagnosis and treatment, short and long-term outcomes.

Study type: Observational (Patient Registry)

Study design: Observational Model: Cohort

Time Perspective: Prospective and retrospective

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Non-small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

I Retrospective cohort

Diagnosis of advanced non-small cell lung cancer from 2012-2016

No interventions assigned to this group

II Prospective cohort

Advanced non-small cell lung cancer with driver gene mutations

No interventions assigned to this group

III Prospective cohort

Non-small cell lung cancer in immuno-therapy;

No interventions assigned to this group

IV Prospective cohort

Non-small cell lung cancer with wild-type driver gene or unknown driver gene status;

No interventions assigned to this group

V Prospective cohort

Advanced non-small lung cancer with wild-type gene treated with anti-Vascular Endothelial Growth Factor (VEGF) drug.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cohort I: diagnosis of advanced non-small cell lung cancer from 2012-2016;
* Cohort II: documented positive driver gene mutations; and diagnosis of advanced non-small cell lung cancer;
* Cohort III: diagnosis of advanced non-small cell lung cancer and in immune-therapy;
* Cohort IV: diagnosis of advanced non-small cell lung cancer, and with wild-type driver gene or unknown driver gene status;
* Cohort V: treated with anti-VEGF drug in first line, diagnosis of advanced non-squamous and non-small cell lung cancer in 6 months before recruit;
* Age\>18 years;
* Provision of written informed consent.

Exclusion Criteria

* not applicable
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking Union Medical College Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yan Xu, M.D.

Role: CONTACT

861069155039

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yan Xu, Dr.

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Xu Y, Zhang L, Fang J, Wang Z, Li J, Li L, Ai B, Nie L, Mu X, Liang L, Zhang S, Zhang Y, Song Y, Song X, Wang Y, Xin T, Jin B, Wang X, Ding C, Wang M. Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study). Thorac Cancer. 2018 Dec;9(12):1795-1800. doi: 10.1111/1759-7714.12865. Epub 2018 Sep 27.

Reference Type DERIVED
PMID: 30264504 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

JS-1410

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prospective Observational Study on ES-SCLC
NCT07173946 NOT_YET_RECRUITING